Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
- 72 Downloads
A platinum doublet has been the standard treatment for patients with advanced non-small cell lung cancer (NSCLC) and good performance status. This treatment results in almost a doubling of 1-yr survival, along with an improvement in quality of life despite treatment-related toxicities. However, platinum-based treatment may be associated with significant toxicity.
Materials and Methods
In this trial, we prospectively evaluated a weekly regimen of docetaxel and gemcitabine for advanced NSCLC. The endpoints of this study included objective response rate, survival, and toxicity. Forty-two patients with previously untreated, advanced NSCLC with PS 0-1 were included. Patients received docetaxel (36 mg/m2) and gemcitabine (600 mg/m2) on d 1, 8, and 15 of a 28-d cycle. Responses were assessed every two cycles. The median age was 63 yr; with 22 males and 20 females; 67% were ≥60 years old; and 38 patients had stage IV disease.
In the intent-to-treat (ITT) analysis of response, 16 patients had a partial response (38%) and 15 patients had stable disease (36%). The 1-yr survival was 48%; median survival for all patients was 11.3 mo and the median progression-free survival was 5.1 mo. Toxicities (≥grade 3) included neutropenia (29%), asthenia (26%), diarrhea (14%), thrombocytopenia (10%), pneumonitis (7%), peripheral neuropathy (5%), peripheral edema (5%), nail changes (2%), and myositis (2%).
This study demonstrated that this non-platinum doublet (docetaxel+gemcitabine) given on a weekly schedule for advanced NSCLC was well tolerated with efficacy comparable to that reported with platinum-based chemotherapy regimens.
Key WordsDocetaxel gemcitabine chemotherapy advanced non-small cell lung cancer phase II
Unable to display preview. Download preview PDF.
- 4.Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2000(2):CD002139.Google Scholar
- 9.Roszkowski K, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27(3):145–157.PubMedCrossRefGoogle Scholar
- 10.Fossella FV, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18(12):2354–2362.PubMedGoogle Scholar
- 18.WHO handbook for reporting results of cancer treatment. Geneva (Switzerland) 1979.Google Scholar
- 20.Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311(7010):899–909.Google Scholar
- 23.Van Meerbeeck JP, et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced NSCLC. In: ASCO 2001.Google Scholar
- 30.J. R. Rigas MC, B. Cole, A. Evans, R. Page, F. Yunus, M. Ruben, H. Ghazal, K. Dragnev. The Dartmouth Non-Platinum Based Chemotherapy Trial Investigators; Dartmouth Medical School, Hanover, NH; Norris Cotton Cancer Center, Lebanon, NH; PPD Development, Wilmington, NC; Texas Cancer Care, Fort Worth, TX; University of Tennessee, Memphis, TN; Florida Cancer Specialist, Bonita Springs, FL; Appalachian Clinical Research, Pikeville, KY; Dartmouth Hitchcock Medical Center, Lebanon, NH. Multicenter Web-based phase III study to test the survival equivalence of non-platinum-based (NPB) vs platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): The Dartmouth NPB Chemotherapy Trial (D0112). In: 2004 ASCO annual meeting 2004.Google Scholar
- 35.Rosell Rea. ERCC1 mRNA based randomized phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV non-small-cell lung cancer. In: ASCO 40th annual meeting 2005.Google Scholar
- 36.Sandler Aea. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial—E4599. In: ASCO annual meeting: 2005; 2005.Google Scholar